News

INHIBITOR Therapeutics, Inc. a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous and…
Read More...

Roche announced that the European Commission has granted conditional marketing authorisation for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab)…
Read More...

Bellicum Pharmaceuticals announced it has entered into an asset purchase agreement under which The University of Texas MD Anderson Cancer Center will acquire Bellicum’s approximately…
Read More...

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two…
Read More...

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co., Ltd. that engages in contract manufacturing and manufacturing development of cell…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab…
Read More...

Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and…
Read More...

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now…
Read More...

AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment…
Read More...

Novartis announced the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active…
Read More...

Mundipharma announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership covers Samsung…
Read More...

Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to…
Read More...

Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in…
Read More...

Neuroptika announced that the first patient was enrolled in a Phase 2 clinical trial of NRO-1 for the treatment of dry eye disease. NRO-1 is a novel therapeutic with the potential to…
Read More...

Twist Bioscience Corporation announced a collaboration with Schrödinger, Inc. to bring the two companies’ technology platforms together to discover new antibody therapeutics against…
Read More...

Azymus Therapeutics, an emerging pharmaceutical company, is advancing 10-years of nano-therapeutic research supported by its AZ Platform. The company's researchers are studying…
Read More...

Bayer and WuXi Biologics have entered into an agreement that WuXi Biologics Germany GmbH will take over operations of one of Bayer’s final drug product manufacturing plants in…
Read More...

Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has entered into exclusive licensing and supply agreements with Rockwell Medical Inc. (Rockwell),…
Read More...

NuMedii, Inc. announced a new partnership with a drug delivery company to develop new therapeutics for ulcerative colitis. The collaboration will bring together NuMedii's NM-001 asset…
Read More...